Dernières nouvelles pour SAB Biotherapeutics (NASDAQ:SABS) Stock

SAB Biotherapeutics

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

SAB Biotherapeutics Inc

Citigroup analyst Ronald Josey maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $753 to $780.

News

Price Target

Analyst Ratings

Citigroup Maintains Buy on Meta Platforms, Raises Price Target to $780

Citigroup analyst Jon Tower maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Neutral and raises the price target from $166 to $185.

Citigroup Maintains Neutral on Brinker International, Raises Price Target to $185

Citigroup analyst Scott Gruber maintains Seadrill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) with a Buy and lowers the price target from $50 to $46.

SDRL

Citigroup Maintains Buy on Seadrill, Lowers Price Target to $46

American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) has outperformed the market over the past 5 years by 6.37% on an annualized basis producing an average annual return of 19.32%. Currently, American Express has a market capitalization of $223.90 billion. 
Buying $100 In AXP: If an investor had bought $100 of AXP stock 5 years ago, it would be worth $243.47 today based on a price of $318.95 for AXP at the time of writing.
<h3>American Express's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738278015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning American Express Stock In The Last 5 Years

Citigroup analyst Scott Gruber maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Neutral and raises the price target from $47 to $48.

Citigroup Maintains Neutral on Valaris, Raises Price Target to $48

Citigroup analyst Asiya Merchant maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and lowers the price target from $82 to $80.

Citigroup Maintains Buy on Western Digital, Lowers Price Target to $80

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $285 to $265.

Citigroup Maintains Buy on Danaher, Lowers Price Target to $265

Citigroup analyst George Choi maintains Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Buy and raises the price target from $64.5 to $67.

Citigroup Maintains Buy on Las Vegas Sands, Raises Price Target to $67

Maxim Group analyst Jason McCarthy maintains Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) with a Buy and raises the price target from $8 to $12.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Maxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

Earnings

HFBL

CORRECTION: Home Federal Bancorp Q2 EPS $0.33, Flat YoY

Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) has outperformed the market over the past 5 years by 18.24% on an annualized basis producing an average annual return of 31.2%. Currently, Cheniere Energy has a market capitalization of $51.65 billion. 
Buying $1000 In LNG: If an investor had bought $1000 of LNG stock 5 years ago, it would be worth $3,918.96 today based on a price of $230.20 for LNG at the time of writing.
<h3>Cheniere Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738277138_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Cheniere Energy 5 Years Ago Would Be Worth This Much Today

Shares of Common Stock are expected to begin trading on the New York Stock Exchange under the ticker symbol "INR." The offering is expected to close on February 3, 2025, subject to customary closing conditions.

IPOs

Infinity Natural Resources Prices Public Offering Of 13.25M Shares Of Class A Common Stock At $20.00 Per Share

Maxim Group analyst Allen Klee initiates coverage on Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) with a Buy rating and announces Price Target of $5.

Initiation

ORKT

Maxim Group Initiates Coverage On Orangekloud Technology with Buy Rating, Announces Price Target of $5

Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) shares are falling in extended trading Thursday after the company <a href="https://www.benzinga.com/pressreleases/25/01/b43355741/walgreens-boots-alliance-suspends-quarterly-dividend-as-company-continues-disciplined-execution-ag">suspended its quarterly dividend</a>.
What Happened: After the market close on Thursday, Walgreens announced its board is suspending its cash dividend as management continues to evaluate its capital allocation policy as part of a longer-term turnaround strategy.
The suspended dividend is expected to help strengthen the company&#8217;s balance sheet by reducing debt over time and improving free cash flow.
&#8220;The company&#8217;s cash needs over the next several years, including with respect to litigation and debt refinancing, were important considerations as part of the decision to suspend the dividend,&#8221; the company said. 
&#8220;WBA leadership remains focused on successfully executing against its strategic priorities and maintaining financial discipline, which it believes will deliver sustained value creation over the long term.&#8221;
<h1 class="wp-block-heading">How To Buy WBA Stock</h1>
By now you're likely curious about how to participate in the market for Walgreens — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share. 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading — either way it allows you to profit off of the share price decline.
WBA Price Action: <a href="http://benzinga.com/quote/wba">Walgreens shares</a> were down 7.77% after-hours, trading at $10.52 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever">Apple Q1 Earnings: Revenue Beat, EPS Beat, iPhone Sales Slip, Installed Base Climbs To All-Time High — &#8216;Our Best Quarter Ever&#8217;</a></li>
</ul>
Photo: Courtesy of Walgreens Boots Alliance.

Dividends

After-Hours Center

Walgreens Boots Alliance Shares Slide As Board Suspends Dividend

For the quarter ended December 31, 2024, the company reported a net loss of $2.0 million, or $0.03 per diluted common share, compared to net income of $0.9 million, or $0.01 per diluted common share, for the quarter ended September 30, 2024, and a net loss of $5.8 million for the fourth quarter of 2023.&nbsp;

BRBS

Blue Ridge Bankshares Q4 EPS $(0.03), Says Regulatory Remediation Efforts On Track

Lake Street analyst Eric Martinuzzi maintains Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) with a Hold and raises the price target from $15 to $16.

EXTR

Lake Street Maintains Hold on Extreme Networks, Raises Price Target to $16

Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) reported its third-quarter financial results after Thursday's closing bell. Here's a look at the<a href="https://www.benzinga.com/pressreleases/25/01/b43352747/boot-barn-holdings-inc-announces-third-quarter-fiscal-year-2025-financial-results"> details from the report.&nbsp;</a>
The Details:&nbsp;Boot Barn reported earnings of $2.43 per share, beating the $2.29 estimate. Quarterly revenue came in at $608.17 million, beating the $607.01 million estimate.
Same-store sales increased 8.6% compared to the prior-year period, comprised of an increase of 8.2% in retail store same-store sales and an increase of 11.1% in e-commerce same-store sales. The company opened 13 new stores, bringing its total store count to 438 as of the quarter end.
Read Next: <a href="https://www.benzinga.com/general/travel/25/01/43343648/all-60-passengers-4-crew-members-onboard-american-airlines-jet-feared-dead-after-midair-collision-official-says">64 Killed In American Airlines Midair Collision Near D.C., Worst US Air Disaster Since 2001&nbsp;</a>
&#8220;I want to thank the entire Boot Barn team for their excellent execution and dedication during a busy holiday season, which resulted in strong third-quarter results and earnings per diluted share above the high end of our guidance range. The strength we saw in the business was once again driven by broad-based growth across all major merchandise categories, channels and geographies, resulting in a consolidated same-store sales increase of 8.6%,&#8221; said John Hazen, Interim CEO.
&#8220;We also grew total sales 16.9% compared to the prior-year period, driven in part by the 13 new stores we opened in the third quarter and the 39 new stores we have opened year-to-date through our third fiscal quarter,&#8221; Hazen added. 
Outlook:&nbsp;Boot Barn raised its fiscal 2025 GAAP EPS guidance from a range of&nbsp;$5.30 to $5.60 to a range of $5.81 to $5.90, versus the&nbsp;$5.76&nbsp;estimate, and raised its fiscal 2025 sales guidance from a range of $1.87 billion to $1.91 billion to&nbsp;a range of $1.91 billion to $1.92 billion, versus the $1.91 billion estimate. 
BOOT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Boot Barn Holdings shares are down 6.60% after-hours at $163 on Thursday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details">Microsoft Shares Slide After Q2 Results, Cloud Revenue Misses Expectations: Details</a>&nbsp;</li>
</ul>
Photo: Courtesy of Boot Barn Holdings, Inc.

Movers

BOOT

Boot Barn Stock Falls After Q3 Report: What To Know

Loop Capital analyst Alton Stump maintains Silgan Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLGN#NYSE">SLGN</a>) with a Buy and raises the price target from $70 to $75.

SLGN

Loop Capital Maintains Buy on Silgan Hldgs, Raises Price Target to $75

Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) has outperformed the market over the past 5 years by 7.19% on an annualized basis producing an average annual return of 20.15%. Currently, Coherent has a market capitalization of $14.03 billion. 
Buying $1000 In COHR: If an investor had bought $1000 of COHR stock 5 years ago, it would be worth $2,656.40 today based on a price of $90.71 for COHR at the time of writing.
<h3>Coherent's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738276219_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COHR

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Barclays analyst George Wang maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Overweight and raises the price target from $91 to $139.

Barclays Maintains Overweight on Celestica, Raises Price Target to $139

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SAB Biotherapeutics (SABS – Research Report) and Vor...

Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Vor Biopharma (VOR)

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report), with a price ...

SAB Biotherapeutics (SABS) Gets a Buy from Oppenheimer

Craig-Hallum analyst Albert Lowe maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report) today and set a price target of $11.00. Th...

Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)

SAB Biotherapeutics GAAP EPS of -$1.12

Oppenheimer analyst Leland Gershell maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report) today and set a price target of $12.00....

Oppenheimer Sticks to Their Buy Rating for SAB Biotherapeutics (SABS)

The year is winding down, but the bull markets are still charging ahead, getting a boost from improved sentiment after the presidential election. W...

These 2 "Strong Buy" Penny Stocks Are Set to Triple (or more), Say Analysts

Craig-Hallum analyst Albert Lowe maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report) today. The company's shares closed yesterd...

SAB Biotherapeutics (SABS) Gets a Buy from Craig-Hallum

SAB BIO announced positive topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers. The study met its prim...

SAB Biotherapeutics announces data from Phase 1 trial of SAB-142

In a report released today, Albert Lowe from Craig-Hallum maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report). The company's sh...

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on SAB Biotherapeutics (SABS – Research Report), with a price...

Comments

SAB Biotherapeutics

Actualités

Dernières nouvelles pour SAB Biotherapeutics (NASDAQ:SABS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL